05:49 PM EDT, 03/20/2024 (MT Newswires) -- HilleVax ( HLVX ) reported a Q4 net loss late Wednesday of $0.78 per diluted share, compared with a loss of $0.56 a year earlier.

Analysts polled by Capital IQ expected a loss of $0.83.

As expected, no revenue for the quarter ended Dec. 31 was reported.

The clinical-stage biopharmaceutical company said it had cash, cash equivalents and marketable securities of $303.5 million as of Dec. 31, compared with $279.4 million at the end of 2022.

Shares of the company closed 7.6% lower in regular trading on Wednesday. It fell a further 1.4% in after-hours activity.

Price: 15.89, Change: -0.22, Percent Change: -1.37